To include your compound in the COVID-19 Resource Center, submit it here.

FDA prolongs review of Lipocine's Tlando

Lipocine Inc. (NASDAQ:LPCN) said FDA extended by three months its review of Tlando testosterone

Read the full 142 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE